Fabry’s disease, an X-linked lysosomal storage disorder caused by mutations in the GLA gene, presents with various clinical manifestations, notably cardiovascular involvement such as Hypertrophic cardiomyopathy (HCM).1 Hypertrophic cardiomyopathy is a heart condition characterized by the thickening of the heart muscle, often resulting in symptoms such as chest pain, shortness of breath, fainting, and, in severe cases, syncope and sudden death. Here, GLA is linked to hypertrophic cardiomyopathy.